Press coverage about Neon Therapeutics (NASDAQ:NTGN) has trended somewhat negative this week, according to Accern Sentiment. Accern identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Neon Therapeutics earned a news impact score of -0.04 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 45.1606001880795 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

NTGN has been the topic of a number of research reports. Morgan Stanley initiated coverage on Neon Therapeutics in a research note on Monday, July 23rd. They set an “overweight” rating and a $23.00 price target on the stock. Cann initiated coverage on Neon Therapeutics in a research note on Monday, July 23rd. They set an “outperform” rating and a $20.00 price target on the stock. Oppenheimer initiated coverage on Neon Therapeutics in a research note on Monday, July 23rd. They set a “$11.74” rating and a $20.00 price target on the stock. Finally, Bank of America initiated coverage on Neon Therapeutics in a research note on Monday, July 23rd. They set a “buy” rating and a $18.00 price target on the stock.

NASDAQ:NTGN traded down $0.23 during mid-day trading on Friday, reaching $11.92. 25,712 shares of the stock were exchanged, compared to its average volume of 101,700. Neon Therapeutics has a 1 year low of $10.21 and a 1 year high of $16.23.

Neon Therapeutics (NASDAQ:NTGN) last released its quarterly earnings results on Monday, August 6th. The company reported ($7.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($7.04). research analysts expect that Neon Therapeutics will post -5.5 EPS for the current fiscal year.

In related news, major shareholder Access Industries Holdings Llc bought 315,000 shares of the stock in a transaction on Friday, June 29th. The shares were bought at an average cost of $16.00 per share, for a total transaction of $5,040,000.00. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink.

Neon Therapeutics Company Profile

Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.

Featured Article: Book Value Per Share in Stock Trading

Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.